BCRX BioCryst Pharmaceuticals Inc.

-0.01  -0%
Previous Close 3.63
Open 3.67
Price To Book 18.1
Market Cap 399,332,774
Shares 110,312,921
Volume 1,634,399
Short Ratio
Av. Daily Volume 2,565,434

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 3 trial to commence summer 2019.
Angioedema attacks in patients with hereditary angioedema (HAE)
Phase 3 data May 21, 2019 met primary endpoint but lower than expectations.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)
Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.
Healthy volunteers
Phase 1 trial to be initiated 2Q 2019 with data due 4Q 2019.
Healthy subjects
Phase 1 trial to commence 2H 2019.
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT
  2. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. BioCryst to Present at Upcoming Investor Conferences
  4. Here's Why BioCryst Pharmaceuticals Is Soaring Today
  5. The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
  6. Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
  7. In less than six hours today, this Durham company's stock has dropped 50 percent
  8. Here's Why BioCryst Pharmaceuticals Collapsed Today
  9. BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial
  10. BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
  11. Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
  12. BioCryst to Present at Bank of America Merrill Lynch Health Care Conference
  13. BioCryst Completes Phase 1 Clinical Trial of Galidesivir
  14. Biocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript
  15. BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
  16. BioCryst: 1Q Earnings Snapshot
  17. BioCryst Reports First Quarter 2019 Financial Results
  18. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  19. Here’s What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX)